C08B37/16

VIRUCIDAL COMPOUNDS AND USES THEREOF
20210137966 · 2021-05-13 ·

The invention relates to virucidal compounds, virucidal compositions comprising thereof and uses thereof in treatment of viral infections, for sterilizations and for disinfections.

Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof
10988600 · 2021-04-27 · ·

A hyaluronic acid product is comprising a cross-linked hyaluronic acid and one or more cyclodextrin molecules, and further comprising a guest molecule capable of forming a guest-host complex with the aminocyclodextrin molecule acting as a host, wherein the guest molecule is a retinoid, preferably adapalene, or a RAM BA. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent.

Process for the preparation of Sugammadex sodium and its novel polymorphic form

The present invention provides an improved process for the preparation of Sugammadex sodium of formula (I) having more than 98.5% purity along with less than 1.0% monohydroxy Sugammadex sodium and less than 0.15% any other known or unknown impurities by HPLC. ##STR00001##

Mechanically interlocked molecules-based materials for 3-D printing

Provided are supramolecular polypseudorotaxane hydrogel compositions and 3-D structures capable of reversible 3-D structural deformation which include (a) a solvent; (b) an at least partially linear polymer, where the polymer further comprises groups capable of covalent crosslinking between the polymers; (ii) at least one first macrocyclic ring which forms a pseudorotaxane with a polymer in the polymer network; and (iii) at least one second macrocyclic ring that does not form the pseudorotaxane. The hydrogel composition has a viscosity which allows for 3-D printing of the hydrogel to form a 3-D structure, and a storage (elastic) modulus after crosslinking that allows for the 3-D structure to undergo reversible 3-D structural deformation upon change of solvent conditions. Also provided are methods of manufacturing the compositions and 3-D structures.

MANGIFERIN AS A PROTECTIVE AGENT AGAINST MITOCHONDRIAL DNA DAMAGE AND SKIN-CARE COMPOSITIONS COMPRISING SAME
20210106601 · 2021-04-15 ·

The invention relates to compounds that provide protective effects against mitochondrial DNA damage. In particular, it relates to mangiferin, ideally in the form of a naturally-occurring mangiferin extract, and to mangiferin-containing compositions and their use as protective agents against mitochondrial DNA damage. Aspects of the invention relate to an additive for a skin care composition, wherein the additive comprises a complex of mangiferin with β-cyclodextrin or a β-cyclodextrin derivative. The invention also relates to skin care compositions comprising the mangiferin complexes, as well as to methods of their preparation. In embodiments, the additive can be used in a sunscreen formulation to protect against UV-induced mtDNA damage.

Methods of treating certain depressive disorders and delirium tremens

The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether β-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurosteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.

Cross-linked Nanoporous Saccharide-based Material and Methods for Fabrication Thereof
20210122875 · 2021-04-29 ·

The present invention discloses a cross-linked nanoporous saccharide-based material comprising saccharides as building blocks, also referred as nanoporous Nanosponge materials. The reaction of saccharides with cross-linkers at different saccharides to cross-linker ratios in one-pot shall allow formation of nanoporous Nanosponge material. This method further allows introduction of new functional groups on this material by the use of suitable cross-linkers and surface grafting agents, and these functional groups shall be able to provide different interaction forces with water, volatile organic vapors (VOCs) and metal ions. Along with larger inner surface area owing to the presence of nanopores or nanocavities in comparison to porous materials, saccharide-based nanoporous Nanosponge materials shall find broad applications in thermal insulation, water retention, hydrophobic finishes, odor removal properties, and metal ions exchange or absorption from water or soil. The nanoporous Nanosponge materials shall be eco-friendly, biodegradable, and allowing recycle or reuse of spent materials.

Cyclodextrin polymer with ultra-fast adsorption performance
10982014 · 2021-04-20 · ·

A novel cyclodextrin polymer with ultra-fast adsorption performance is provided. A cyclodextrin polymer having a three-dimensional network structure is obtained by mixing and crosslinking a cyclodextrin with a rigid crosslinking agent and a non-rigid crosslinking agent at a certain temperature. The polymer is capable of adsorbing a plurality of organic pollutants in water at an ultra-fast rate, and the polymer after adsorption is easily regenerated by simple washing at a normal temperature, and is repeatedly used without causing a decrease in adsorption performance.

Pre-Mixed, Ready-To-Use Pharmaceutical Compositions

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

TREATMENT OF CANCER

Provided are methods relating to compositions that include a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.